CorMedix surged 59% since March, driven by strong DefenCath sales and its acquisition of Melinta Therapeutics, diversifying its portfolio. DefenCath's robust Q1 and Q2 sell-in exceeded expectations, ...
The Central and Eastern Europe Fund, Inc. remains attractive with low portfolio P/E of 8.58x and 12% earnings yield. Read why CEE CEF is a Buy.
Lauren (Hansen) Holznienkemper is a lead editor for the small business vertical at Forbes Advisor, specializing in HR, payroll and recruiting solutions for small businesses. Using research and writing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback